1. A Phase II Study of Combined Chemoradiotherapy for Limited Disease–Small-Cell Lung Cancer
- Author
-
Satoru Watanabe, Noriaki Sunaga, Ichirou Naruse, Atsushi Takise, Takeyuki Makimoto, Naoto Fueki, Masatomo Mori, Koichi Minato, Satoshi Tsuchiya, Taisuke Nomoto, Shinichi Ishihara, Yoshikazu Takei, Koji Sato, Ryusei Saito, Hideki Hoshino, and Go Kobayashi
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Phases of clinical research ,Gastroenterology ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Esophagitis ,Humans ,Carcinoma, Small Cell ,Lung cancer ,Survival rate ,Etoposide ,Aged ,Chemotherapy ,Leukopenia ,business.industry ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Thrombocytopenia ,Surgery ,Regimen ,Treatment Outcome ,Oncology ,Doxorubicin ,Female ,Cisplatin ,medicine.symptom ,business ,Chemoradiotherapy ,medicine.drug - Abstract
A study to evaluate the efficacy of cisplatin, doxorubicin, and etoposide chemotherapy with combined radiotherapy was undertaken in 26 patients with limited disease-small-cell lung cancer. Patients were treated with cisplatin (80 mg/m 2 ) intravenously (i.v.) on day 1, doxorubicin (30 mg/m 2 ) i.v. on day I, and etoposide (80 mg/m 2 ) i.v. on days 1, 3, and 5, every 4 weeks for four cycles. Thoracic irradiation of 40 Gy in 20 fractions was delivered during 4 weeks to the primary site starting on day 8 of the second cycle of chemotherapy. The objective response rate was 100%. A complete response was observed in 10 patients (38%). The median survival time was 23 months, and the 3-year survival rate was 42%. Seven patients (27%) continued to survive at least 8 years and remain free from disease. Grade III/IV leukopenia was observed in 25 patients (96%). Grade III/IV thrombocytopenia developed in 19 patients (73%). Grade III/IV esophagitis was not seen. Interstitial pneumonitis occurred in two patients. This regimen is effective and has acceptable toxicity for use in the treatment of limited disease-small-cell lung cancer.
- Published
- 2000